Slingshot members are tracking this event:
U.S. FDA Approves IMBRUVICA (ibrutinib) for First-line Treatment of Chronic Lymphocytic Leukemia
Do you think this event is important to the companies below? How will it affect their stock price?
Slingshot Insights Explained
Mar 04, 2016
Don’t see a project related to the catalyst you care about?
Related Keywords Imbruvica, Ibrutinib, Fda Approval, Chronic Lymphocytic Leukemia